CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...